Skip to main content

Table 2 Non-serious adverse events during erlotinib treatment

From: Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Adverse event Number of patients (%) Number of events
Rash 36 (58.1%) 43
Diarrhoea 17 (27.4%) 26
Dry skin 11 (17.7%) 15
Pruritus 9 (14.5%) 10
Asthenia 5 (8.1%) 9
Conjunctivitis 6 (9.7%) 8
Back pain 7 (11.3%) 8
Cough 8 (12.9%) 8
Alopecia 7 (11.3%) 7
Anaemia 5 (8.1%) 6
Growth of eyelashes 5 (8.1%) 5
Nausea 4 (6.5%) 5
Increased blood AP 5 (8.1%) 5
Weight loss 4 (6.5%) 5
Headache 5 (8.1%) 5
Dyspnoea 5 (8.1%) 5
Decreased appetite 4 (6.5%) 4